The largest prospective trial of ROS1 TKI in East Asia (including Taiwan, Japan, Korea, China) reported a CNS transfer rate of 18.1% in ROS 1-positive NSCLC at baseline, which is consistent with our study (33). Here, ROS1 is linked to non-small cell lung carcinoma.